WEBULL
WebtradeDownload

Lantheus Holdings (LNTH) Wins FDA Approval For BRAVNETSA, Is 7% Undervalued Enough?

Simply Wall St · 1d ago

Lantheus Holdings (LNTH) just received final FDA approval for BRAVNETSA, a radiopharmaceutical judged bioequivalent and therapeutically equivalent to LUTATHERA for treating somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors.

For investors watching the tape, Lantheus Holdings has eased off its highs in recent months, with the share price down over the past 90 days. The year to date share price return sits at 48.61% and the 1 year total shareholder return is 87.81%, which reflects the company’s recent performance despite recent cooling ahead of catalysts such as the BRAVNETSA approval and other product and corporate developments.

Spot emerging radiopharma momentum by comparing Lantheus Holdings with other specialist healthcare players screened in the 38 healthcare AI stocks.

For Lantheus Holdings, the pullback over the past quarter sits awkwardly next to strong 1-year and year-to-date gains. Is this about the underlying radiopharma engine, or simply sentiment cooling after a strong run, and how does that feed into valuation from here?

Most Popular Narrative: 7% Undervalued

Lantheus Holdings closed at $99.97, against a widely followed fair value estimate of about $107.22, which frames the current merger spread and BRAVNETSA news flow in valuation terms rather than just headlines.

Recent acquisitions (Evergreen and Life Molecular Imaging) enhance Lantheus's manufacturing capabilities, broaden its product portfolio, and provide an immediate and scalable entry into high-growth radiopharmaceutical and neuroimaging markets. This is expected to support both revenue growth and longer-term operating margin improvements.

See why 79 investors see Lantheus Holdings as 7% undervalued.

Result: Fair Value of $107.22 (UNDERVALUED)

Still, the Lantheus Holdings story can change quickly if PYLARIFY pressure deepens or if reimbursement shifts erode pricing power faster than analysts expect.

Find out about the key risks to this Lantheus Holdings narrative.

Next Steps

Curious whether the optimism around Lantheus Holdings really holds up on your own scoreboard? Act quickly, stress test the thesis, and weigh those 4 key rewards.

Looking for more Lantheus Holdings style ideas?

If you do not broaden your watchlist beyond Lantheus Holdings, you might miss opportunities in other areas where risk, quality, and income look more compelling.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.